Evidence map›Paper›PMID 42068413›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.

Ronald Chow, Daniel Zhang, Samy Kannout, Andreas Ma, Cindy Zheng, Ayden Blayne, Aaron Dou, Sumeet Talwar, Rouhi Fazelzad, Hope S Rugo and 7 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ronald ChowPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. ronald.chow@uhn.ca.
Daniel ZhangSiebel School of Computing and Data Science, University of Illinois Urbana-Champaign, Champaign, IL, USA.
Samy KannoutTemerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Andreas MaTemerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Cindy ZhengOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Ayden BlayneTemerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Aaron DouPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Sumeet TalwarOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Rouhi FazelzadPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Hope S RugoDepartment of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Christina H RuhlmannDepartment of Oncology, Odense University Hospital, Odense, Denmark.
Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Mary Louise AffrontiDuke University School of Nursing, Duke University, Durham, NC, USA.
Jennifer LeighOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Florian ScottéDépartement Interdisciplinaire D'Organisation Des Parcours Patients, Gustave-Roussy, Université Paris-Saclay, 94800, Villejuif, France.
Lawson EngPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
MASCC Antiemetic Study Group and the MASCC Emerging Toxicities Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAntibody-drug conjugates (ADC) have emerged as an important part of systemic treatment across disease sites. To date, there is no robust pooled prevalence estimate of nausea and vomiting induced by ADCs. Establishing such estimates is essential to determine if ADC-induced nausea and vomiting (ADCINV) represents a clinically significant problem warranting further research into antiemetic prophylaxis. Our aim is to report the prevalence of reported ADCINV across literature.

methodsA systematic search of Medline, Embase, Cochrane CENTRAL and Web of Science was conducted from database inception until September 24, 2025. Articles were included if they reported nausea and/or vomiting due to ADCs used in cancer treatment, in the abstract. Pooled prevalence was reported. Subgroup analysis was conducted by ADC. Meta-regression was conducted by age and sex. Quality assessment was conducted. Type I error was set at 0.05.

resultsA total of 209 studies with 15,493 patients were included. Thirty-nine percent (95%CI, 36-42%) of patients experience any nausea, and 26% (95%CI, 23-29%) experience any vomiting. Younger patients are more likely to experience nausea; each 10-year increase in age is associated with a 12% decrease in nausea rates. Higher emetogenic ADCs include trastuzumab deruxtecan, sacituzumab govitecan, brentuximabvedotin and patritumab deruxtecan. Lower emetogenic agents include disitimab vedotin, telisotuzumab vedotin and rovalpituzumab tesirine. DISCUSSION: This is the first study to report prevalence of ADCINV across ADCs. It is a prevalent adverse effect akin to chemotherapy-induced nausea and vomiting that should be viewed as clinically relevant and further investigated to help develop optimal strategies related to antiemetics.

Indexed as

Antineoplastic AgentsImmunoconjugatesNauseaNeoplasmsVomitingAntiemeticsHumansPrevalenceAntiemeticsAntineoplastic AgentsImmunoconjugatesAntibody drug conjugateNauseaVomiting

Identifiers

PMID42068413
PMCPMC13135589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.